Xingming Youjian Grants AviadoBio Exclusive Option for Overseas Rights to Optogenetic Therapy UGX202

According to the terms of the agreement,AviadoBio will exercise its option within the option period.UGX202Conduct Evaluation, if the option is exercised,AviadoBio will obtainUGX202Global exclusive development and commercialization rights outside of Greater China，UgeneX is acceptable.ObtainIncluding down paymentPayment, including R&D and sales milestone payments totaling over$400 million in cash, along with corresponding sales royalties.

Dr. Kai Wu, President of UgeneXRepresentation："We are delighted to collaborate with AviadoBio to advance the clinical application of ophthalmic gene therapy and promote global cooperation."UgeneX has been committed to developing innovative gene therapies in ophthalmology to improve the quality of life for patients with visual impairments. This collaboration not onlyReflects both parties' commitment toHigh Confidence in the Future Clinical Potential and Market Prospects of UGX202, and at the same timeIs an important milestone for our company to step into the international market, fullyReflectTo usThe team's international perspective and R&D capabilities, as well as the global value of the pipeline。”

AviadoBio CEO Lisa Deschamps stated："We are delightedCapable of expanding the neurodegenerative disease clinical-stage pipeline portfolio from the brain to ophthalmology, bringing usTargeted DeliveryVector、High-efficiency Target ProteinAnd the core of rapid transformationTechnology and Advantages，Can be applied in retinitis pigmentosaAnd other retinal diseases. Our team has extensive experience in the development of ocular gene therapies and looks forward to collaborating withUgeneXTeamwork, Co-creatingUGX202 Therapeutic Pipeline."

UGX202 is UgeneX's new generation optogenetics product under research.，Through self-researchAAV Virus as a Vector, Carrying Wide-Spectrum and High-Sensitivity Innovative Photoreactive Proteins, Specifically Infects Retinal Ganglion Cells and Confers Light-Sensing Function, Reconstructing the Visual Pathway for Patients with Mid-to-Late Stage Photoreceptor Degenerative Diseases. UGX202, as a "Universal" Innovative Gene Therapy Across Gene Mutations, Breaks Through the Limitation of Rare Disease Patient Numbers, Suitable for Multiple Disease Populations, Including Retinitis Pigmentosa, Stargardt Disease, Choroideremia, and Advanced Dry Age-Related Macular Degeneration.

UgeneXFounded in2021YearJuly, is aFocus on Ophthalmic DiseasesInnovativenessGene Therapy Product DevelopmentThe company, hasCumulatively received over 100 million yuan in investment。The company team has more than 15 years of practical experience in the research and development of innovative therapies in the fields of ophthalmology and neurobiology., establishedOphthalmology Gene Therapy Innovation Technology PlatformInAnd a product pipeline that is internationally leading, with indications covering retinitis pigmentosa, dry age-related macular degeneration, and other retinal diseases. Currently, the company's core pipeline optogenetic product has entered the clinical research stage, and it is expected to become a new generation therapy for patients with mid-to-late stage photoreceptor degenerative diseases.。

AviadoBio is committed to tirelessly pursuing a cure by transforming groundbreaking science and precision delivery into revolutionary drugs that improve the lives of patients with neurological disorders.Method. With a deep understanding of the brain and a series of proprietary gene therapy platforms and delivery technologies,AviadoBio is working hard to overcome the challenge of delivering the right drug to the right location. AviadoBio, with a neuroanatomy-oriented approach,InnovationMethod, Committed toMaximize the potential of gene therapy to halt or potentially reverse neurodegenerative diseases.AviadoBio, founded on the groundbreaking research from King's College London and the UK Dementia Research Institute, has a leadership team with extensive experience in gene therapy development, delivery, and commercialization, offering a unique advantage in successfully bringing transformative medicines to patients. For more information, please visitwww.aviadobio.com。

About PackGene Biotech